The DOI matches its Crossref record.
The β-Cell in Diabetes: From Molecular Genetics to Clinical Research
Abstract
Pancreatic insulin secretion rates can be accurately derived by mathematical deconvolution of peripheral C-peptide concentrations either by using individual C-peptide kinetic parameters obtained by analysis of the decay curve of biosynthetic human C-peptide or by using published group parameters with appropriate adjustments for age and degree of obesity. Since the cross-reactivity of proinsulin and related peptides is low (< 10%) in many C-peptide assays, this experimental approach avoids the spurious increase in insulin immunoreactivity resulting from cross-reactivity with proinsulin and related peptides in the insulin assay. Application of this technique has demonstrated that the phenotypic expression of β-cell dysfunction differs in subjects with different genetic mechanisms of non-insulin-dependent diabetes mellitus (NIDDM). Subjects who have maturity-onset diabetes of the young (MODY) due to mutations in the glucokinase gene demonstrate different patterns of altered insulin secretion when compared with subjects who have mutations in the MODY1 gene on chromosome 20. Glucokinase mutations affect the ability of the β-cell to detect and respond to small increases in glucose above the basal level. However, compensatory mechanisms operative in vivo, which include a priming effect of glucose on insulin secretion, limit the severity of the observed insulin secretory defect, resulting in a generally mild clinical course in these subjects. In contrast, mutations in the MODY1 gene are associated with an inability to increase insulin secretion as the plasma glucose concentration increases above 7–8 mmol/l and the normal priming effect of glucose on insulin secretion is lost. These characteristics of the dose-response relationships between glucose and insulin secretion result in a more severe degree of hyperglycemia than observed in subjects with glucokinase mutations, and these subjects more frequently need insulin treatment. These alterations are evident in prediabetic subjects with normal glucose levels who carry the MODY1 mutation, suggesting that defective β-cell function is the primary pathogenetic defect in the diabetic syndrome in these subjects. Studies performed in the classic form of NIDDM demonstrate that subjects with mild glucose intolerance and normal fasting glucose concentrations and glycosylated hemoglobin levels consistently demonstrate defective β-cell function. These results are consistent with studies in the Zucker diabetic fatty rat, an animal model of NIDDM in which prediabetic animals demonstrate extensive alterations in expression of multiple genes involved in the regulation of insulin secretion. It thus appears that abnormal β-cell function is present at a relatively early stage in the evolution of NIDDM, even before the onset of overt hyperglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3)
Yamagata, K., Oda, N., Kaisaki, P. J., Menzel, S., Furuta, H., Vaxillaire, M., Southam, L., Cox, R. D., Lathrop, G. M., Boriraj, V. V., et al. (1996) · Nature · doi:10.1038/384455a0 · Cited by 1,614
Self-citationPathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
“Although debate still continues about which defect—insulin resistance or impaired insulin secretion—initiates the cascade of events leading to overt diabetes mellitus, essentially all patients who have type 2 diabetes with elevated fasting plasma glucose levels have a defect in insulin secretion (15).”
BackgroundInfluentialKulkarni, R. N., Brüning, J. C., Winnay, J. N., Postic, C., Magnuson, M. A., & Kahn, C. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80546-2 · Cited by 1,148
Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young
Fajans, S. S., Bell, G. I., & Polonsky, K. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmra002168 · Cited by 1,123
Self-citationPancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Gunton, J. E., Kulkarni, R. N., Yim, S., Okada, T., Hawthorne, W. J., Tseng, Y.-H., Roberson, R. S., Ricordi, C., O’Connell, P. J., Gonzalez, F. J., et al. (2005) · Cell · doi:10.1016/j.cell.2005.05.027 · Cited by 492
Ferrannini, E. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.4.0336 · Cited by 451
Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion
Lang, J. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00043.x · Cited by 347
Troglitazone action is independent of adipose tissue.
Burant, C. F., Sreenan, S., Hirano, K., Tai, T. A., Lohmiller, J., Lukens, J., Davidson, N. O., Ross, S., & Graves, R. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119839 · Cited by 334
Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
Laron Dwarfism and Non-Insulin-Dependent Diabetes Mellitus in the Hnf-1 α Knockout Mouse
Lee, Y.-H., Sauer, B., & Gonzalez, F. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.3059 · Cited by 262
Beta cell function and its relation to insulin action in humans: a critical appraisal
Ferrannini, E., & Mari, A. (2004) · Diabetologia · doi:10.1007/s00125-004-1381-z · Cited by 262
Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation
Carpentier, A., Mittelman, S. D., Lamarche, B., Bergman, R. N., Giacca, A., & Lewis, G. F. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.6.e1055 · Cited by 254
Nutrient Control of Insulin Secretion in Isolated Normal Human Islets
Henquin, J.-C., Dufrane, D., & Nenquin, M. (2006) · Diabetes · doi:10.2337/db06-0868 · Cited by 228
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Self-citationReduced β-cell mass and altered glucose sensing impair insulin-secretory function in βIRKO mice
Otani, K., Kulkarni, R. N., Baldwin, A. C., Krutzfeldt, J., Ueki, K., Stoffel, M., Kahn, C. R., & Polonsky, K. S. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00533.2001 · Cited by 185
Self-citationPhilipson, L. H. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.129702 · Cited by 99
Androgen Excess in Pancreatic β Cells and Neurons Predisposes Female Mice to Type 2 Diabetes
Navarro, G., Allard, C., Morford, J. J., Xu, W., Liu, S., Molinas, A. J. R., Butcher, S. M., Fine, N. H. F., Blandino-Rosano, M., Sure, V. N., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98607 · Cited by 80
Jaleel, A., Klaus, K. A., Morse, D. M., Karakelides, H., Ward, L. E., Irving, B. A., & Nair, K. S. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00351.2009 · Cited by 23
Metadata
- Authors
- Polonsky, K. S.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1995-06-01
- Volume
- 44
- Issue
- 6
- Pages
- 705-717
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2096573235
- Cited by
- 158
- References
- 0
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.